Evgen Pharma Share Discussion Threads

[lovewinshatelosses] 10/12/2020 09:29

I also agree that a new broker might help. Someone in the company, or closely associated, needs to ramp up the marketing considerably, as I have suggested a few times now.
All that said, for the first time in a while here, I am tempted to add more, on the basis of greater confidence in the direction of travel, rather than feeling like I am just taking a punt while averaging down, as a couple of my recent buys have felt like.
Mindful of 'famous last words' though, I will put a pin in the enthusiasm for now! GLA.

[timbo003] 10/12/2020 09:18

It is odd that Finncap continue to attribute no value whatsoever to either the Pneumonia indication, or the Juvenescence collaboration 😕

Time for a new broker?

[moneymunch] 10/12/2020 08:41

EARLY REPORTING FROM SFX-01's COVID-19 PATIENT TRIALS.....CONFIRMED!!!

9 patients administered so far with full results expected Q4 2021, although unblinded data will be reviewed after 100 patients!!! Gla ;-)


Up to the 7th of December nine patients had been recruited and depending on availability of COVID-19 patients and other patients with ARDS, data could be available in the final quarter of 2021. In addition, a Data Safety and Monitoring Board will review unblinded data after 100 patients have been treated with SFX-01 or placebo.

[moneymunch] 10/12/2020 08:24

and who are we in collaboration with....would we need patent filings and a scientific paper prepared before disclosure if it was merely academia???? Gl ;-)


Solid tumour oncology target

In a collaboration which will be disclosed when patent filings and a scientific paper have been prepared, strong preclinical data has been generated when SFX-01 was evaluated in a model of a cancer with very poor life expectancy, and for which current treatments are limited.



In particular, in vitro studies with patient-derived cell lines showed dose-dependent reduction in proliferation and migration. Further, in vivo orthotopic xenograft models, treatment with SFX-01 increased disease-free survival and lengthened tumour progression times, an effect that is synergistic with radiotherapy.



Further preclinical work will be initiated shortly to complete the data set required for a clinical trial application and/or partnering discussions. The preclinical work should be completed by the middle of 2021 and a phase Ib/II could commence in Q1 of 2022.

[timbo003] 10/12/2020 08:18

It is good to see that they will now focus on just two high value areas

Any inbound proposals that look like a bit of a longshot will not automatically be allocated resource, That's the way to do it 🙂

[lovewinshatelosses] 10/12/2020 08:09

Yep. I'm also satisfied with that update. All we need now is for the share price to start reflecting the potential we have here. GLA.

[timbo003] 10/12/2020 08:08

One interesting sentence in the report caught my eye

"Patients will be drawn from both hospital and community settings"

This is new. In the it specifies that it will only be patients with community acquired pneumonia

I would imagine that this will increase the number of patients available for recruitment significantlty

Perhaps a good question to ask the new CEO?

[moneymunch] 10/12/2020 07:53

A very exciting update on proceedings imho....multiple UPside potential on multiple fronts....Gla holders ;-)

[moneymunch] 10/12/2020 07:52

and misiniformation....;-)

[hodhasharon] 10/12/2020 07:50

Go careful MM. You'll be accused of obsessive ramping. :-)

[moneymunch] 10/12/2020 07:50

Lol timbo.....i did notice.....and it was ridiculous for anyone else to suggest otherwise, or at least anyone to become so incensed for suggesting that early reporting would be highly likely.... Gl ;-)

[timbo003] 10/12/2020 07:47

Good solid update

I like the new well defined strategy

...and just in case anyone didn't notice there will be an interim analysis by the data safety monitoring board after 100 patients in the ARDs study.

[moneymunch] 10/12/2020 07:46

No weakness that i can see....Gl ;-)

[amaretto1] 10/12/2020 07:38

Should i say add !

[amaretto1] 10/12/2020 07:37

I've still got powder for this one..Any weakness I'll come in.

[moneymunch] 10/12/2020 07:29

Multiple UPside potential on multiple fronts......all for a ridiculously low £12m!!! Gla ;-)

NON-CLINICAL PROGRAMMES

Our long-term toxicology and manufacturing process development work has continued. Initial data suggest that we will be able to demonstrate an acceptable toxicology profile for conducting clinical trials in chronic diseases where longer term dosing is required. These data are consistent with our observations of patients who received SFX-01 for extended periods in the mBC trial.



Scale-up of our formulation and manufacturing processes has progressed. In particular, a commercial scale process for producing a key intermediate in drug substance manufacture has been developed by a well-regarded contract manufacturing organisation. Also, the stabilised sulforaphane conjugate has demonstrated good flow properties in prototype solid dose formulations, enabling larger scale production.

[moneymunch] 10/12/2020 07:24

Undoubtedly, with enough cash until this time next year.....and undoubted transformational potential from current rock bottom low.....Fill Ya Boots!!! Gla ;-)

[amaretto1] 10/12/2020 07:16

A steady ship.. with a good looking future.

[moneymunch] 10/12/2020 07:16

9 patients administered so far with full results expected Q4 2021, although unblinded data will be reviewed after 100 patients, and therefore could be made public imho if positive indications are observed....or not!!! Gla ;-)


Up to the 7th of December nine patients had been recruited and depending on availability of COVID-19 patients and other patients with ARDS, data could be available in the final quarter of 2021. In addition, a Data Safety and Monitoring Board will review unblinded data after 100 patients have been treated with SFX-01 or placebo.

[moneymunch] 10/12/2020 07:11

Solid tumour oncology target

In a collaboration which will be disclosed when patent filings and a scientific paper have been prepared, strong preclinical data has been generated when SFX-01 was evaluated in a model of a cancer with very poor life expectancy, and for which current treatments are limited.



In particular, in vitro studies with patient-derived cell lines showed dose-dependent reduction in proliferation and migration. Further, in vivo orthotopic xenograft models, treatment with SFX-01 increased disease-free survival and lengthened tumour progression times, an effect that is synergistic with radiotherapy.



Further preclinical work will be initiated shortly to complete the data set required for a clinical trial application and/or partnering discussions. The preclinical work should be completed by the middle of 2021 and a phase Ib/II could commence in Q1 of 2022.



Blood cancer target

Professor Philip Eaton at Queen Mary University of London has shown that SFX-01 inhibits activity of the non-receptor phosphotyrosine phosphatase, SHP2 (coded by the ptpn11 gene). SHP2 is thought to be a significant factor in some cancers and we have recently agreed to support work in well-renowned university to investigate whether SFX-01 has potential in a specific blood cancer disease.

[moneymunch] 10/12/2020 07:08

The Directors estimate that the cash held by the Group together with known receivables will be sufficient to support the current level of activities into at least late 2021.

[moneymunch] 10/12/2020 07:03

RNS Number : 1297I
Evgen Pharma PLC
10 December 2020






Evgen Pharma plc

("Evgen" or "the Company" or "the Group")



Half year Report



Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its unaudited interim results for the six months ended 30 September 2020.



Operational highlights

· Dr Huw Jones appointed as Chief Executive Officer

· Completion of first out-licensing deal with Juvenescence for use of Sulforadex® technology in non-pharmaceutical markets. Up to $10.5m receivable in milestones with royalties on sales

· Phase IIb/III trial using SFX-01 for acute respiratory distress syndrome ("ARDS") including COVID-19 patients sponsored by Dundee University, with grant funding from LifeArc; the ''STAR'' trial (SFX-01 treatment for acute respiratory infections)

· Patient recruitment commenced in STAR trial post the period end with data potentially available in Q4 2021.

· Strong pre-clinical data generated in a new solid tumour indication; requirements for and design of a Phase Ib/IIa trial being assessed

· Pre-clinical work commenced in a blood cancer indication based on new evidence that SFX-01 inhibits the SHP2 pathway

· Pre-clinical work proceeding to support SFX-01 use in metastatic breast cancer patients who have become resistant to CDK4/6 drugs

· Good progress in process development to scale up manufacturing and formulation of SFX-01



Financial highlights

· Financial performance in-line with expectations:

o Loss post tax of £1.8m (2019: loss of £1.6m)

o Cash outflow from operations of £1.9m (2019: outflow of £1.7m)

o Cash balance at 30 September 2020 of £2.3m (30 September 2019: £5.1m)



Dr Huw Jones, Chief Executive Officer of Evgen Pharma, said: "I am delighted to have joined Evgen Pharma during a period of such positive news for the Company. Substantial progress was made in the half year in business development and in particular in our STAR trial where patients with community acquired pneumonia from any infection including COVID-19 can be recruited. I look forward to updating the market and our shareholders on our next cancer indication in due course, where preliminary pre-clinical data look compelling. We continue to demonstrate the huge potential of our pipeline and are excited for the future progression of this."

[moneymunch] 09/12/2020 22:29

and more research , hot off the press that further highlights SFX-01's panacea potential....Gla ;-)))


News Release 8-Dec-2020

Reductive stress in neuroblastoma cells aggregates protein and impairs neurogenesis

Further understanding is needed of the redox change called reductive stress and its impact on the onset and progression of neurodegeneration.

University of Alabama at Birmingham

..............

"Our data suggest that, despite the association of oxidative stress and neuronal damage, RS can play a crucial role in promoting proteotoxicity, and thereby lead to neurodegeneration," Namakkal-Soorappan said. "Moreover, this study adds to the emerging view that the regulation of redox homeostasis, and its impact on diverse diseases, is part of a complex process in which appropriate doses of antioxidants are required only in response to an oxidative or toxic challenge in cells or organisms."

...................

In the current study, the researchers used sulforaphane to establish RS in proliferating and differentiating Neuro 2a neuroblastoma cells grown in culture. Sulforaphane activates Nrf2/ARE signaling, leading to antioxidant augmentation. Specifically, they found that sulforaphane-mediated Nrf2 activation diminished reactive oxygen species in a dose-dependent manner leading to RS. The resulting RS abrogated oxidant signaling and impaired endoplasmic reticulum function, which promoted protein aggregation and proteotoxicity, and impaired neurogenesis. This included elevated Tau and α-synuclein and their co-localization with other protein aggregates in the cells.

Namakkal-Soorappan says they were also surprised to see that acute RS impaired neurogenesis, as measured by reduced neurite outgrowth and length, and that maintaining the cells in sustained RS conditions for five consecutive generations dramatically reduced differentiation and prevented the formation of axons.

This impairment of neurogenesis occurs through activation of the pathogenic GSK3β/Tau cascade to promote phosphorylation of Tau and create proteotoxicity.

Intriguingly, there have been reports of increased levels of enzymes that can promote RS, both in the brains of Alzheimer's patients and in the post-mortem brains of Alzheimer's and Parkinson's patients. Also, attempts to promote neurogenesis in neurodegenerative diseases using small molecule antioxidants have had poor outcomes.

"Therefore, clinical evidence warrants a closer investigation and further understanding of redox changes and their impact at the onset and progression of neurodegeneration," Namakkal-Soorappan said.

Neurodegenerative diseases, including Alzheimer's, Parkinson's and Huntington's, are a major health problem in aging populations throughout the world.

[moneymunch] 09/12/2020 21:14

Ps , I'll have a berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane salad and chips please. :-)

[moneymunch] 09/12/2020 20:33

Excellent research that undoubtedly highlights SFX-01's chances for Covid....Gla ;-)

Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies

December 9, 2020

This article was originally published here

Clin Transl Allergy. 2020 Dec 3;10(1):58. doi: 10.1186/s13601-020-00362-7.

ABSTRACT

There are large between- and within-country variations in COVID-19 death rates. Some very low death rate settings such as Eastern Asia, Central Europe, the Balkans and Africa have a common feature of eating large quantities of fermented foods whose intake is associated with the activation of the Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) anti-oxidant transcription factor.

There are many Nrf2-interacting nutrients (berberine, curcumin, epigallocatechin gallate, genistein, quercetin, resveratrol, sulforaphane) that all act similarly to reduce insulin resistance, endothelial damage, lung injury and cytokine storm.

They also act on the same mechanisms (mTOR: Mammalian target of rapamycin, PPARγ:Peroxisome proliferator-activated receptor, NFκB: Nuclear factor kappa B, ERK: Extracellular signal-regulated kinases and eIF2α:Elongation initiation factor 2α).

They may as a result be important in mitigating the severity of COVID-19, acting through the endoplasmic reticulum stress or ACE-Angiotensin-II-AT1R axis (AT1R) pathway.

Many Nrf2-interacting nutrients are also interacting with TRPA1 and/or TRPV1. Interestingly, geographical areas with very low COVID-19 mortality are those with the lowest prevalence of obesity (Sub-Saharan Africa and Asia).

It is tempting to propose that Nrf2-interacting foods and nutrients can re-balance insulin resistance and have a significant effect on COVID-19 severity.

It is therefore possible that the intake of these foods may restore an optimal natural balance for the Nrf2 pathway and may be of interest in the mitigation of COVID-19 severity.